Nicholas Fraser Brown

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. John F. Marshall · 5 shared papers, 2020–2025 · strength 0.80
   • Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534↗
   • Paper Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer. DOI 10.1016/j.pan.2024.02.013↗
   • Paper CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-19-2163↗
2. Lauren C. Cutmore · 3 shared papers, 2020–2025 · strength 0.59
   • Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534↗
   • Paper Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer. DOI 10.1016/j.pan.2024.02.013↗
   • Paper Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ducta… DOI 10.1016/j.pan.2020.02.006↗
3. Yaohe Wang · 2 shared papers, 2020–2025 · strength 0.37
   • Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534↗
   • Paper Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ducta… DOI 10.1016/j.pan.2020.02.006↗
4. Renato B. Baleeiro · 1 shared paper, 2025 · strength 0.26
   • Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534↗
5. Louisa S. Chard Dunmall · 1 shared paper, 2025 · strength 0.26
   • Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534↗
6. Zuoyi Zhao · 1 shared paper, 2025 · strength 0.26
   • Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534↗
7. Deepak Raj · 2 shared papers, 2020–2021 · strength 0.23
   • Paper CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-19-2163↗
   • Paper Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ducta… DOI 10.1016/j.pan.2020.02.006↗
8. Kate M. Moore · 2 shared papers, 2020–2021 · strength 0.21
   • Paper CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-19-2163↗
   • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗
9. Hemant Mahendrakumar Kocher · 1 shared paper, 2021 · strength 0.12
   • Paper CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-19-2163↗
10. John F. Maher · 1 shared paper, 2020 · strength 0.11
    • Paper Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ducta… DOI 10.1016/j.pan.2020.02.006↗
11. Claire S. Reader · 1 shared paper, 2020 · strength 0.10
    • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗
12. Sara Maria David Trabulo · 1 shared paper, 2020 · strength 0.10
    • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.